Crisugabalin
Crisugabalin is a selective GABA analog in development for the treatment of chronic pain. It has a wider therapeutic index than pregabalin, which has a similar mechanism of action. In China, it was approved in May 2024 for the treatment of diabetic peripheral neuropathic pain and approved in July 2024 for the treatment of postherpetic neuralgia. In the United States, it is in Phase III trials as of 2023. The drug can be administered with or without food.